Home » 2014 (Page 56)
Yearly Archives: 2014
आयुर्वेद न्यूट्रास्यूटीकल्स ; अधिक गर्मी के कारण होने वाली तकलीफो से बचने के लिये ………
आयुर्वेद की विशेषता यही है कि सभी मौसम के लिये सभी के लिये आयुर्वेद के मनीषियों ने मौसम से प्राप्त सभी वस्तुओ के सटीक उपयोग के लिये combinations दे दिये है /
गर्मी के मौसम मे गर्म हवाओ के चलने और लू लपट high degree temperature के चलते हुये बहुत सी तकलीफे शरीर मे अचानक पैदा होने की स्तिथि बन जाती है , इन सभी अवस्थाओ से बचने के लिये नीचे लिखे nueutraceutical को अपनाइये और फायदा उठाइये ;
साम्ग्री सब आप्के किचन मे मिल जायेगी /
१- एक छोटा प्याज , बड़ा हो तो आधा कर ले
२- एक कच्चा छोटा आम / अमिया
३-१५ -२० पुदीना की पत्ती / अधिक भी छोड़ सकते है
४- एक टुकड़ा अदरख
५- एक चम्मच जल जीरा मसाला पाउडर
५- आधा चम्मच काली मिर्च
६- स्वादानुसार काला नमक
७- एक या दो चम्मच शक्कर / चीनी / गुड़
८- आधा या…
View original post 277 more words
Late-stage fluorination, what do you think ?
Hi Everyone, I have really been appreciating the visits to my blog. I had resurrected this dormant site blog a while ago and hoped I could get a fair number of visits. I have been overwhelmed with the response. Some of the posts were clear winners, like the Revlimid case, for sure. I, recently, came across this review in Organic Process Research & Development and realized there probably would be two sides to this argument.
Late-stage fluorination. The current review in OPRD can be found at Michael G. Campbell and Tobias Ritter*, “Late-Stage Fluorination: From Fundamentals to Application”, Org. Process Res. Dev. 2014, 18, 474−480
doi: 10.1021/op400349g
I remember, many years ago, discussing this with a colleague about adding a fluorine group to a molecule. We both agreed that it would be far better to add a fluorine early on the synthesis, so if there were side-products, you would…
View original post 315 more words
EU approves Takeda’s bowel drug Entyvio
Hot on the heels of an approval in the US, regulators in Europe have now also given Takeda’s Entyvio (vedolizumab) the nod for two inflammatory bowel diseases. The European Commission has granted Marketing Authorisation for use of the gut-selective humanised monoclonal antibody to treat adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD).
Read more at: http://www.pharmatimes.com/Article/14-05-27/EU_approves_Takeda_s_bowel_drug_Entyvio.aspx#ixzz334DL7xQJ
Unusual structural and electronic properties make skin pigments superior radical scavengers

A black and insoluble biopolymer called eumelanin and other types of melanin together determine skin and hair color, particularly for dark phenotypes. Eumelanin is also a soft, biocompatible nanomaterial with technological potential. However, previous studies of this substance have primarily been carried out with synthetic samples. In the journal Angewandte Chemie, Italian researchers have now revealed why natural eumelanin is significantly superior to the synthetic version as a radical scavenger, antioxidant, and photo-protectant.
Thanks to its unusual optoelectronic, dielectric, metal-binding, and radical-scavenging properties, eumelanin could be useful for a variety of technical applications, including organic electronic components or antioxidants for plastics. However, it was recently discovered that the properties of synthetic eumelanin are significantly different from those of the natural product.
Within pigment cells, eumelanin is produced enzymatically from tyrosine or DOPA. An important intermediate step in this process is the isomerization of dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA). In…
View original post 279 more words
Brain scans spot possible clues to chronic fatigue syndrome
Seeking better insight into chronic fatigue syndrome, a new brain scan investigation has pinpointed what could be the first evidence of a connection between nerve cell inflammation and the onset of this debilitating and somewhat mysterious illness, researchers say.
The finding stems from a small PET scan study, led by Yasuhito Nakatomi of the RIKEN Center for Life Science Technologies in Hyogo, Japan. The study involved just nine patients with chronic fatigue syndrome and 10 healthy participants.
However, the investigators believe that their initial results are the first to show that neuro-inflammation is a distinct feature of chronic fatigue syndrome. This inflammation affects specific areas of the brain that are commonly linked with the kind of fatigue, pain, depression, and thought-process difficulties long associated with the syndrome, the researchers noted.
“While the results will need to be confirmed in larger studies, it is a very exciting finding,” said Suzanne…
View original post 563 more words
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....











